Fellowship · Kansas City, KS
Sponsored by University of Kansas School of Medicine
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
European heart journal · 2022 · 1,074 citations · Patrick Moriarty
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
The New England journal of medicine · 2023 · 716 citations · Patrick Moriarty
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).
Nature medicine · 2022 · 202 citations · Patrick Moriarty
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
European heart journal · 2022 · 176 citations · Patrick Moriarty
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
The lancet. Diabetes & endocrinology · 2021 · 201 citations · Patrick Moriarty
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Circulation · 2024 · 81 citations · Patrick Moriarty
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.
Nature medicine · 2023 · 121 citations · Patrick Moriarty
Lipoprotein Apheresis: Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement From the American Heart Association.
Arteriosclerosis, thrombosis, and vascular biology · 2024 · 58 citations · Patrick Moriarty